Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Completed 9Terminated 4Withdrawn 2Active not recruiting 2Unknown 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Lymphoid 1

Conditions

Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumors 1Advanced Solid Malignancies 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × urelumab × Clear all
NCT02253992 2020-10-05

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Bristol-Myers Squibb

Phase 1/2 Terminated
232 enrolled 17 charts
LymphoidOther solid neoplasm

Advanced Solid Tumors

NCT00309023 2015-10-12

Study of BMS-663513 in Patients With Advanced Cancer

Bristol-Myers Squibb

Phase 1/2 Terminated
115 enrolled
Tumor-Agnostic

Neoplasms

NCT00351325 2009-09-04

A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies

Bristol-Myers Squibb

Phase 1 Terminated
45 enrolled

Advanced Solid Malignancies

NCT00461110 2009-09-04

A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)

Bristol-Myers Squibb

Phase 1 Terminated
35 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡